I Walk the Line: How to Tell MDS From Other Bone Marrow Failure Conditions

Current Hematologic Malignancy Reports

Volumn 9, Issue 4, 2014, Pages 389-399

  Gondek, Lukasz P ^a   DeZern, Amy E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Aplastic anemia; Bone marrow failure; Large granular lymphocytosis; Molecular markers; Myelodysplastic syndrome; Paroxysmal nocturnal hemoglobinuria; SNP arrays; Somatic mutations

Indexed keywords

BONE MARROW; BONE MARROW DISEASES; HUMAN; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PROGNOSIS;

BONE MARROW; BONE MARROW DISEASES; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84926688654     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-014-0224-3     Document Type: Review

References (96)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. NEngl J Med. 2009;361(19):1872–85.
2. Young NS. Acquired bone marrow failure. Blood: principles and practice of hematology. Philadelphia: JB Lippincott; 1995.
3. Alter BP. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. HematologyAmSocHematolEducProgram. 2007;29–39.
4. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61(19):7233–9.
5. Swerdlow SH, Campo E, Harris NL, Jaffe E, Pileri SA, Stein H et al. WHO classification of tumours of the haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer (IARC); 2008.
6. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943–64. doi:10.1182/blood-2013-03-492884. This is a consensus report on diagnosis and treatment of MDS from European LeukemiaNet and provides a thorough review of the evidence through its publication date.
7. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385–95. doi:10.1182/blood-2007-03-082404.
8. Sole F, Luno E, Sanzo C, Espinet B, Sanz GF, Cervera J, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90(9):1168–78.
9. Schanz J, Steidl C, Fonatsch C, Pfeilstocker M, Nosslinger T, Tuechler H, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011;29(15):1963–70. doi:10.1200/JCO.2010.28.3978.
10. Pierre RV, Hoagland HC. Age-associated aneuploidy: loss of Y chromosome from human bone marrow cells with aging. Cancer. 1972;30(4):889–94.
11. Wiktor A, Rybicki BA, Piao ZS, Shurafa M, Barthel B, Maeda K, et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer. 2000;27(1):11–6.
12. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011;118(17):4690–3. doi:10.1182/blood-2011-03-342642.
13. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006;20(3):458–62.
14. Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing’s sarcoma. Bone Marrow Transplant. 1998;22(10):971–9. doi:10.1038/sj.bmt.1701471.
15. Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood. 2008;112(4):965–74. doi:10.1182/blood-2008-02-130435.
16. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–506. doi:10.1056/NEJMoa1013343. This large study describes novel somatic mutations in MDS. Authors identified somatic mutations in a large cohort of 439 patients. Mutations in TP53, EZH2, ETV6, RUNX1, and ASXL1 were found to be predictors of poor overall survival independently of established risk factors.
17. Tiu RV, Gondek LP, O’Keefe CL, Elson P, Huh J, Mohamedali A, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011;117(17):4552–60. doi:10.1182/blood-2010-07-295857.
18. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010;24(3):101–22.
19. Tsangaris E, Klaassen R, Fernandez CV, Yanofsky R, Shereck E, Champagne J, et al. Genetic analysis of inherited bone marrow failure syndromes from one prospective, comprehensive and population-based cohort and identification of novel mutations. J Med Genet. 2011;48(9):618–28. doi:10.1136/jmg.2011.089821.
20. Vulliamy TJ, Walne A, Baskaradas A, Mason PJ, Marrone A, Dokal I. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis. 2005;34(3):257–63. doi:10.1016/j.bcmd.2004.12.008.
21. Du HY, Pumbo E, Ivanovich J, An P, Maziarz RT, Reiss UM, et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood. 2009;113(2):309–16.
22. Armanios M. Syndromes of telomere shortening. Annu Rev Genomics Hum Genet. 2009;10:45–61. doi:10.1146/annurev-genom-082908-150046.
23. Calado RT, Cooper JN, Padilla-Nash HM, Sloand EM, Wu CO, Scheinberg P, et al. Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia. 2012;26(4):700–7. doi:10.1038/leu.2011.272.
24. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010;304(12):1358–64.
25. Aubert G, Hills M, Lansdorp PM. Telomere length measurement-caveats and a critical assessment of the available technologies and tools. Mutat Res. 2012;730(1–2):59–67. doi:10.1016/j.mrfmmm.2011.04.003.
26. Gadalla SM, Cawthon R, Giri N, Alter BP, Savage SA. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging (Albany NY). 2010;2(11):867–74.
27. Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001;97(4):895–900.
28. Calado RT, Young NS. Telomere diseases. NEngl J Med. 2009;361(24):2353–65.
29. Poloni A, Serrani F, Berardinelli E, Maurizi G, Mariani M, Costantini B, et al. Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome. Leuk Res. 2013;37(11):1538–44. doi:10.1016/j.leukres.2013.07.022.
30. Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, et al. Telomere length in myelodysplastic syndromes. Leuk Lymphoma. 2011;52(8):1528–36. doi:10.3109/10428194.2011.568648.
31. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 2000;37(1):15–29.
32. Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009;94(2):264–8.
33. Dameshek W. Riddle: what do aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH) and “hypoplastic” leukemia have in common? (Editorial). Blood. 1967;30(2):251–4.
34. Young NS. The problem of clonality in aplastic anemia: Dr. Dameshek’s riddle, restated. Blood. 1992;79:1385–92.
35. Afable 2nd MG, Wlodarski M, Makishima H, Shaik M, Sekeres MA, Tiu RV, et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood. 2011;117(25):6876–84. doi:10.1182/blood-2010-11-314393.
36. Woll PS, Kjallquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014;25(6):794–808. doi:10.1016/j.ccr.2014.03.036.
37. Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754–62. doi:10.1200/JCO.2008.18.2246.
38. de Planque MM, van Krieken JH, Kluin-Nelemans HC, Colla LP, van der Burgh F, Brand A, et al. Bone marrow histopathology of patients with severe aplastic anaemia before treatment and at follow-up. Br J Haematol. 1989;72(3):439–44.
39. Young NS, Maciejewski J. The pathology of acquired aplastic anemia. N Engl J Med. 1997;336(19):1365–72.
40. Leguit RJ, van den Tweel JG. The pathology of bone marrow failure. Histopathology. 2010;57(5):655–70. doi:10.1111/j.1365-2559.2010.03612.x.
41. Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood. 1996;87(11):4831–8.
42. DeZern AE, Pu J, McDevitt MA, Jones RJ, Brodsky RA. Burst-forming unit-erythroid assays to distinguish cellular bone marrow failure disorders. Exp Hematol. 2013;41(9):808–16. doi:10.1016/j.exphem.2013.04.013.
43. Fureder W, Paulitsch-Buckingham A, Rabitsch W, Jager E, Schwarzinger I, Sperr WR, et al. Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience. Wien Klin Wochenschr. 2014. doi:10.1007/s00508-013-0484-2.
44. Geissler K, Hinterberger W, Bettelheim P, Haas O, Lechner K. Colony growth characteristics in chronic myelomonocytic leukemia. Leuk Res. 1988;12(5):373–7.
45. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048–57. doi:10.1182/blood-2012-06-435297.
46. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905–13. doi:10.1056/NEJMoa1114885.
47. Ishida F, Matsuda K, Sekiguchi N, Makishima H, Taira C, Momose K, et al. STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci. 2014;105(3):342–6. doi:10.1111/cas.12341.
48. Saunthararajah Y, Molldrem JL, Rivera M, Williams A, Stetler-Stevenson M, Sorbara L, et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol. 2001;112(1):195–200.
49. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes. Blood. 2012. doi:10.1182/blood-2012-03-420489. This report instituted a new (revised) prognostic scoring system for MDS that is now being implemented in the clinical setting.
50. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–65.
51. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549–57.
52. Gondek LP, Tiu R, O’Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008;111(3):1534–42.
53. Mohamedali A, Gaken J, Twine NA, Ingram W, Westwood N, Lea NC, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood. 2007;110(9):3365–73.
54. Tiu RV, Gondek LP, O’Keefe CL, Huh J, Sekeres MA, Elson P, et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol. 2009;27(31):5219–26.
55. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114(15):3285–91. doi:10.1182/blood-2009-04-215814.
56. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009;113(25):6403–10.
57. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gaken J, Lea NC, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010;116(19):3923–32. doi:10.1182/blood-2010-03-274704.
58. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179–81. doi:10.1038/ng.2413.
59. Ewalt M, Galili NG, Mumtaz M, Churchill M, Rivera S, Borot F, et al. DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia. Blood Cancer J. 2011;1(3):e9. doi:10.1038/bcj.2011.7.
60. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153–8. doi:10.1038/leu.2011.44.
61. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328–33. doi:10.1038/nature13038.
62. Itzykson R, Kosmider O, Fenaux P. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. Best Pract Res Clin Haematol. 2013;26(4):355–64. doi:10.1016/j.beha.2014.01.001.
63. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24(5):1094–6. doi:10.1038/leu.2010.52.
64. Yoshida K, Sanada M, Kato M, Kawahata R, Matsubara A, Takita J, et al. A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Leukemia. 2011;25(1):184–6. doi:10.1038/leu.2010.241.
65. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia. 2012;26(1):101–5. doi:10.1038/leu.2011.298.
66. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010;95(10):1668–74. doi:10.3324/haematol.2010.025494.
67. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788–800. doi:10.1111/j.1365-2141.2009.07697.x.
68. Gelsi-Boyer V, Trouplin V, Roquain J, Adelaide J, Carbuccia N, Esterni B, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151(4):365–75. doi:10.1111/j.1365-2141.2010.08381.x.
69. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–7. doi:10.1038/leu.2013.336. Authors performed targeted sequencing of 104 genes in a large cohort of 944 patients with various subtypes of MDS. Somatic mutations were found in nearly 90 % of patients. Incorporation of somatic mutation status of 14 selected genes into existing risk factors improved overall survival prediction of IPSS-R scoring system.
70. Chen TC, Hou HA, Chou WC, Tang JL, Kuo YY, Chen CY, et al. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J. 2014;4:e177. doi:10.1038/bcj.2013.74.
71. Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78–87. doi:10.1038/leu.2013.269.
72. Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A, et al. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol. 2012;5:4. doi:10.1186/1756-8722-5-4.
73. Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, et al. Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms. Eur J Haematol. 2014;92(3):189–94. doi:10.1111/ejh.12223.
74. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665–7. doi:10.1038/ng.620.
75. Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010;24(10):1799–804. doi:10.1038/leu.2010.167.
76. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376–82. doi:10.1200/jco.2011.40.7379. Study involved 288 patients with low-risk MDS. The mutation status of 22 genes was assessed and incorporated into Low-Risk Prognostic Scoring System. EZH2 mutations identified in 29 % of patients with low-risk MDS was an adverse risk factor in a multivariable model.
77. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384–95. doi:10.1056/NEJMoa1103283. Authors described SF3B1 mutations in a large cohort of 354 patients with MDS. SF3B1 was mutated in 20 % of cases and was enriched for in patients with ring siderobalsts (65 %). Mutated SF3B1 was also found to be a favorable prognostic factor in MDS.
78. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–9. doi:10.1038/nature10496.
79. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2012;44(1):53–7. doi:10.1038/ng.1031.
80. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012;119(14):3203–10. doi:10.1182/blood-2011-12-399774.
81. Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012;120(16):3173–86. doi:10.1182/blood-2012-05-430876.
82. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239–46. doi:10.1182/blood-2011-09-377275.
83. Matsuda K, Ishida F, Ito T, Nakazawa H, Miura S, Taira C, et al. Spliceosome-related gene mutations in myelodysplastic syndrome can be used as stable markers for monitoring minimal residual disease during follow-up. Leuk Res. 2012;36(11):1393–7. doi:10.1016/j.leukres.2012.07.019.
84. Harada Y, Harada H. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations. J Cell Biochem. 2011;112(2):425–32. doi:10.1002/jcb.22974.
85. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166–75. doi:10.1038/13793.
86. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257):904–8.
87. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009;27(36):6109–16.
88. Al-Kali A, Quintas-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, et al. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013;88(5):365–9. doi:10.1002/ajh.23410.
89. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet. 2013;45(10):1232–7. doi:10.1038/ng.2731.
90. Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V, et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia. 2013;27(6):1401–3. doi:10.1038/leu.2013.35.
91. Laborde RR, Patnaik MM, Lasho TL, Finke CM, Hanson CA, Knudson RA, et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia. 2013;27(10):2100–2. doi:10.1038/leu.2013.97.
92. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18–24. doi:10.1038/ng.2495.
93. Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 2013;45(8):937–41. doi:10.1038/ng.2698.
94. Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C, et al. SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia. 2013;27(10):2072–5. doi:10.1038/leu.2013.145.
95. Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood. 2013;122(18):3169–77. doi:10.1182/blood-2012-11-469619.
96. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–27. doi:10.1182/blood-2013-08-518886. Mutation analysis in 738 patients identified oncogenic mutations in nearly 80 % of patients with MDS. Subclonal analysis also revealed the set of candidate driver mutations leading to clonal evolution. Leukemia-free survival was closely related to the number of driver mutations and deteriorated as the number of driver mutations increased.